Invesco Ltd. Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Invesco Ltd. increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 24.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,006,462 shares of the company’s stock after buying an additional 979,858 shares during the quarter. Invesco Ltd. owned about 1.30% of Moderna worth $208,169,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Orion Portfolio Solutions LLC boosted its holdings in Moderna by 65.1% in the third quarter. Orion Portfolio Solutions LLC now owns 3,661 shares of the company’s stock valued at $245,000 after acquiring an additional 1,443 shares during the last quarter. MML Investors Services LLC grew its holdings in shares of Moderna by 21.6% during the 3rd quarter. MML Investors Services LLC now owns 33,895 shares of the company’s stock worth $2,265,000 after purchasing an additional 6,018 shares during the period. Nomura Asset Management Co. Ltd. increased its position in Moderna by 1.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 114,335 shares of the company’s stock worth $7,641,000 after purchasing an additional 1,635 shares in the last quarter. Geode Capital Management LLC raised its holdings in Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Finally, Toronto Dominion Bank lifted its position in Moderna by 23.7% during the third quarter. Toronto Dominion Bank now owns 131,477 shares of the company’s stock valued at $8,787,000 after buying an additional 25,177 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on MRNA shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Leerink Partners reduced their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Morgan Stanley lowered their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $58.70.

Moderna Stock Performance

Shares of Moderna stock opened at $26.20 on Friday. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The firm’s 50-day simple moving average is $31.56 and its 200-day simple moving average is $41.01. The firm has a market cap of $10.13 billion, a PE ratio of -2.82 and a beta of 2.23.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.